Author: Ali, Ahmed S.; ASattar, Mai A.; Kareem, Shahed; Kutbi, Dina; Aljohani, Hanin; Bakhshwin, Duaa; Alsieni, Mohammed; Alkreathy, Huda M.
Title: Pharmacological basis for the potential role of Azithromycin and Doxycycline in management of COVID-19 Cord-id: lf6jka8x Document date: 2021_1_10
ID: lf6jka8x
Snippet: A novel corona virus SARS-CoV-2 has led to an outbreak of the highly infectious pandemic COVID-19 complicated viral pneumonia. Patients with risk factors frequently develop secondary infections where the role of appropriate antibiotics is mandatory. However, the efforts of drug repurposing lead to recognizing the role of certain antibiotics beyond the management of infection. The current review provided the detailed antiviral, immunomodulatory effect, unique pharmacokinetic profile of two antibi
Document: A novel corona virus SARS-CoV-2 has led to an outbreak of the highly infectious pandemic COVID-19 complicated viral pneumonia. Patients with risk factors frequently develop secondary infections where the role of appropriate antibiotics is mandatory. However, the efforts of drug repurposing lead to recognizing the role of certain antibiotics beyond the management of infection. The current review provided the detailed antiviral, immunomodulatory effect, unique pharmacokinetic profile of two antibiotics namely azithromycin (AZ) and doxycycline (DOX). It summarizes current clinical trials and concerns regarding the safety issues of these drugs. Azithromycin (AZ) has amazing lung tissue access, wide range antibacterial efficacy, conceivable antiviral action against COVID-19. It also showed efficacy when combined with other antiviral drugs in limited clinical trials, but many clinicians raise concerns regarding cardiovascular risk in susceptible patients. DOX has a considerable role in the management of pneumonia, it has some advantages including cardiac safety, very good access to lung tissue, potential antiviral, and immunomodulation impact by several mechanisms. The pharmacological profiles of both drugs are heightening considering these medications for further studies in the management of COVID-19.
Search related documents:
Co phrase search for related documents- abcb1 gene and acute respiratory: 1, 2
- abstract novel corona virus and acute respiratory: 1, 2
- abstract novel corona virus and acute respiratory syndrome sars: 1, 2
- acid synthesis and acute respiratory: 1, 2, 3, 4, 5, 6, 7
- acid synthesis and acute respiratory syndrome sars: 1, 2, 3, 4, 5
- acute ali lung injury and adhesion molecule: 1
- acute ali lung injury and adjunctive therapy: 1
- acute ali lung injury and low cost available: 1
- acute ards respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6
- acute ards respiratory distress syndrome and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and long duration: 1, 2, 3, 4
- acute ards respiratory distress syndrome and low cost available: 1
- acute ards respiratory distress syndrome develop and adhesion molecule: 1
- acute respiratory and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory and low cost available: 1, 2, 3
- acute respiratory syndrome sars and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- acute respiratory syndrome sars and low cost available: 1, 2
Co phrase search for related documents, hyperlinks ordered by date